drugset / Trial / NCT05214001
Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
RandomizedParallel-groupOpen-labelTreatment
Summary
In a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.
Timeline
- Start
- 2022-06-30
- Primary completion
- 2024-04-15
- Completion
- 2024-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ubrogepant | Small molecule | 50 mg | Oral |
| Subject | almotriptan | Small molecule | 12.5 mg | Oral |